Vect-Horus

Vect-Horus

Designing and developing peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2017201820192020202120222023
Revenues<1m<1m<1m<1m<1m<1m<1m
% growth(87 %)30816 %41 %(69 %)152 %-15 %
EBITDA(2.3m)(1.7m)(2.5m)(3.2m)(3.5m)--
% EBITDA margin(111289 %)(270 %)(276 %)(1129 %)(480 %)--
Profit(1.5m)(<1m)(1.5m)(2.2m)(2.5m)--
% profit margin(70589 %)(112 %)(163 %)(756 %)(340 %)--

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
*

€2.5m

Early VC
*

€3.5m

Early VC
N/A

€6.7m

Series D
N/A

€5.3m

Valuation: €33.5m

36.7x EV/LTM Revenues

-13.3x EV/LTM EBITDA

Series D
Total FundingAUD30.6m

Recent News about Vect-Horus

Edit
More about Vect-Horusinfo icon
Edit

Vect-Horus is a biotechnology company focused on enhancing the delivery of therapeutic and imaging agents across biological barriers using its proprietary targeting technology. The company serves pharmaceutical and biotechnology firms by providing solutions that improve the efficacy and precision of drug delivery systems. Operating in the healthcare and life sciences market, Vect-Horus employs a business model that involves partnerships, licensing agreements, and collaborative research projects to generate revenue. By leveraging its innovative technology, Vect-Horus aims to address unmet medical needs and improve patient outcomes.

Keywords: biotechnology, drug delivery, targeting technology, therapeutic agents, imaging agents, pharmaceutical, biotechnology firms, healthcare, life sciences, partnerships.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.